Item 2. Unregistered Sales of Equity Securities
Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds.
During the three months ended
June 30, 2025, we issued 10,000 shares of common stock to an advisor in exchange for services. The shares of common stock were issued in
reliance upon an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act.
43
Item 6. Exhibits.
The following exhibits are
filed with this Quarterly Report on Form 10-Q:
Exhibit No.
Description
4.1
Form of Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on June 24, 2025).
10.1
Form of Inducement Offer Letter (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on June 24, 2025).
31.1
Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32*
Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. § 1350 As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101
The following financial statements from the Company’s Quarterly
Report on Form 10-Q for the quarter ended June 30, 2025, formatted in Inline XBRL: (i) Balance Sheets as of June 30, 2025 and December
31, 2024 (unaudited); (ii) Statements of Operations for the three and six months ended June 30, 2025 and 2024 (unaudited); (iii) Statements
of Stockholders’ Equity (Deficit) for the three and six months ended June 30, 2025 and 2024 (unaudited); (iv) Statements of Cash
Flows for the six months ended June 30, 2025 and 2024 (unaudited); and (v) Notes to the Financial Statements (unaudited).
104
The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, formatted in Inline XBRL (included as Exhibit 101).
*
Furnished herewith.
44
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
OS THERAPIES INCORPORATED
Date: August 18, 2025
By:
/s/ Paul Romness
Paul Romness
Chief Executive Officer
(Principal Executive Officer)
Date: August 18, 2025
By:
/s/ Christopher Acevedo
Christopher Acevedo
Chief Financial Officer
(Principal Financial and Accounting Officer)
45
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.